HUP9900666A2 - Új fenantridinszármazékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények - Google Patents

Új fenantridinszármazékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP9900666A2
HUP9900666A2 HU9900666A HUP9900666A HUP9900666A2 HU P9900666 A2 HUP9900666 A2 HU P9900666A2 HU 9900666 A HU9900666 A HU 9900666A HU P9900666 A HUP9900666 A HU P9900666A HU P9900666 A2 HUP9900666 A2 HU P9900666A2
Authority
HU
Hungary
Prior art keywords
hydrogen atom
pipe powder
alkyl
powder
pipe
Prior art date
Application number
HU9900666A
Other languages
English (en)
Inventor
Hermann Amschler
Rolf Beume
Hildegard Boss
Thomas Bär
Dieter Flockerzi
Karl-Josef Goebel
Beate Gutterer
Armin Hatzelmann
Dietrich Häfner
Hans-Peter Kley
Thomas Martin
Christian Schudt
Wolf-Rüdiger Ulrich
Original Assignee
Byk Gulden Lomberg Chemische Fabrik Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19603321A external-priority patent/DE19603321A1/de
Application filed by Byk Gulden Lomberg Chemische Fabrik Gmbh. filed Critical Byk Gulden Lomberg Chemische Fabrik Gmbh.
Publication of HUP9900666A2 publication Critical patent/HUP9900666A2/hu
Publication of HUP9900666A3 publication Critical patent/HUP9900666A3/hu
Publication of HU221380B1 publication Critical patent/HU221380B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A cím szerinti vegyületek (I) általánős képletében R1 jelentésehidrőxil-, alkőxi-, ciklőalkőxi- vagy ciklőalkil-metőxi-csőpőrt vagyflűőrral teljesen vagy részlegesen helyetesített alkőxicsőpőrt, R2jelentése hidrőxil-, alkőxi-, ciklőalkőxi- vagy ciklő-alkil-etőxi-csőpőrt vagy flűőrral teljesen vagy részlegesen helyettesített alkőxi-csőpőrt, vagy R1 és R2 együtt 1-2 szénatőmős akilén-diőxi-csőpőrtőtképez, R3 jelentése hidrőgénatőm vagy alkőlcsőpőrt, R31 jelentésehidrőgénatőm vagy alkilcsőpőrt, vagy R3 és R11 együtt 1-4 szénatőmősalkiléncsőpőrtőt képez, R4 jelentése hidrőgénatőm vagy alkilcsőpőrt,R5 jelentése hidrőgénatőm, R51 jelentése hidrőgénatőm, vagy R5 és R51 együtt tővábbi kötét képez, R6 jelentése R7 általhelyettesített fenilcsőpőrt, ahől R7 jelentése -COOR71 vagy -CON(R72)R73 csőpőrt, ahől R71 jelentése hidrőgénatőm, alkil-,ciklőalkil- vagy ciklőalkil-metil-csőpőrt és R72 és R73 jelentéseegymástól függetlenül hidrőgénatőm, alkil-, ciklőalkil-, vagyciklőalkil-metil-csőpőrt és sóik értékes brőnchiális gyógyászatihatóanyagők. ŕ
HU9900666A 1996-01-31 1997-01-30 Phosphodiesterase inhibitor phenanthridines derivatives and use thereof HU221380B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19603321A DE19603321A1 (de) 1996-01-31 1996-01-31 Neue Phenanthridine
EP96101791 1996-02-08
PCT/EP1997/000402 WO1997028131A1 (de) 1996-01-31 1997-01-30 Neue phenanthridine

Publications (3)

Publication Number Publication Date
HUP9900666A2 true HUP9900666A2 (hu) 1999-06-28
HUP9900666A3 HUP9900666A3 (en) 2000-04-28
HU221380B1 HU221380B1 (en) 2002-09-28

Family

ID=26022482

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900666A HU221380B1 (en) 1996-01-31 1997-01-30 Phosphodiesterase inhibitor phenanthridines derivatives and use thereof

Country Status (19)

Country Link
US (1) US6191138B1 (hu)
EP (1) EP0882021B1 (hu)
JP (1) JP4138003B2 (hu)
KR (1) KR100454781B1 (hu)
AT (1) ATE233735T1 (hu)
BR (1) BR9707233A (hu)
CA (1) CA2245142C (hu)
CY (1) CY2473B1 (hu)
CZ (1) CZ289340B6 (hu)
DE (1) DE59709437D1 (hu)
DK (1) DK0882021T3 (hu)
EA (1) EA001205B1 (hu)
EE (1) EE03523B1 (hu)
ES (1) ES2194180T3 (hu)
HU (1) HU221380B1 (hu)
PT (1) PT882021E (hu)
SI (1) SI0882021T1 (hu)
UA (1) UA48216C2 (hu)
WO (1) WO1997028131A1 (hu)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0882021T1 (en) * 1996-01-31 2003-10-31 Altana Pharma Ag New phenanthridines
PL190685B1 (pl) * 1997-07-25 2005-12-30 Altana Pharma Ag Nowe pochodne tetrazolu, środek farmaceutyczny oraz zastosowanie
JP2001510827A (ja) * 1997-07-25 2001-08-07 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 置換６−フェニルフェナントリジン
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
ES2242594T3 (es) * 1999-01-15 2005-11-16 Altana Pharma Ag N-oxidos de fenantridinas con una acitvidad inhidora de pde-iv.
CA2359449A1 (en) 1999-01-15 2000-07-20 Beate Gutterer Phenanthridine-n-oxides with pde-iv inhibiting activity
EP1163226B1 (en) * 1999-01-15 2007-03-14 ALTANA Pharma AG Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
AU2289400A (en) * 1999-01-15 2000-08-01 Byk Gulden Lomberg Chemische Fabrik Gmbh 6-arylphenanthridines with pde-iv inhibiting activity
CN1152864C (zh) 1999-01-15 2004-06-09 奥坦纳医药公司 具有pde-iv抑制活性的苯基菲啶类化合物
EP2193808A1 (en) 1999-08-21 2010-06-09 Nycomed GmbH Synergistic combination
AU782908B2 (en) 2000-01-11 2005-09-08 Altana Pharma Ag Phenanthridine-N-oxides
WO2002006238A1 (en) * 2000-07-14 2002-01-24 Altana Pharma Ag Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
AU2001281965A1 (en) * 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Novel 6-phenylphenanthridines
WO2002006270A1 (en) * 2000-07-14 2002-01-24 Altana Pharma Ag Novel 6-heteroarylphenanthridines
AU2001269126A1 (en) * 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Phenanthridine n-oxides
AU2001284444B2 (en) * 2000-09-06 2006-05-25 Mitsubishi Tanabe Pharma Corporation Preparations for oral administration
DE60236850D1 (de) * 2001-02-15 2010-08-12 Mitsubishi Tanabe Pharma Corp Tabletten, die in der mundhöhle schnell zerfallen
PL374014A1 (en) * 2002-08-17 2005-09-19 Altana Pharma Ag Novel phenanthridines having pde 3/4 inhibiting properties
ATE353217T1 (de) * 2002-08-29 2007-02-15 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
JP4587294B2 (ja) * 2002-08-29 2010-11-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしての２−ヒドロキシ−６−フェニルフェナントリジン
CA2533635A1 (en) * 2003-07-31 2005-02-10 Altana Pharma Ag Novel 6-phenylphenantridines
JP2007500686A (ja) * 2003-07-31 2007-01-18 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規の６−フェニルフェナントリジン
MXPA06002521A (es) * 2003-09-05 2006-06-20 Altana Pharma Ag Uso de inhibidores de pde4 para el tratamiento de diabetes mellitus.
JP4728259B2 (ja) * 2004-02-18 2011-07-20 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 効果的なホスホジエステラーゼ（ｐｄｅ）４インヒビターとしての新規のグアニジニル置換されたヒドロキシ−６−フェニルフェナントリジン
RS52916B (en) 2004-03-03 2014-02-28 Takeda Gmbh NEW HYDROXY-6-HETEROARYLPHENANTRIDINES AND THEIR USE AS PDE4 INHIBITORS
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
CA2558375A1 (en) * 2004-03-09 2005-09-15 Altana Pharma Ag Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
NZ549254A (en) * 2004-03-10 2010-06-25 Nycomed Gmbh Amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
WO2005087744A1 (en) * 2004-03-10 2005-09-22 Altana Pharma Ag Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
JP2007527898A (ja) * 2004-03-10 2007-10-04 アルタナ　ファルマ　アクチエンゲゼルシャフト ジフルオロエトキシ置換された新規のヒドロキシ−６−フェニルフェナントリジン及びｐｄｅ４インヒビターとしてのそれらの使用
DE602005027866D1 (de) 2004-09-08 2011-06-16 Nycomed Gmbh 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4-inhibitoren
EP1791847A2 (en) 2004-09-08 2007-06-06 Altana Pharma AG Novel 3-thia-10-aza-phenanthrene derivatives
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
NZ589278A (en) 2005-03-02 2012-04-27 Nycomed Gmbh Selected salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives
CA2599376C (en) * 2005-03-08 2014-05-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
CA2599368A1 (en) * 2005-03-09 2006-09-14 Nycomed Gmbh Amido-substituted 6-phenylphenanthridines
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007104035A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP5420534B2 (ja) 2007-05-31 2014-02-19 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101067069B1 (ko) * 2009-03-09 2011-09-22 부경대학교 산학협력단 트리플루오로아세트산을 이용한 페난트리딘 유도체의 제조방법
CN102179655B (zh) * 2011-06-01 2013-09-04 柳州市久日工程机械有限公司 履带梁拼搭气动工装
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
JP7234470B2 (ja) 2015-10-30 2023-03-08 トーヨーカネツ株式会社 立体自動倉庫

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786031A (fr) * 1971-07-08 1973-01-08 Rhone Poulenc Sa Nouveaux derives de la phenanthridine, leur preparation et les compositions medicinales qui les contiennent
US4309545A (en) * 1980-07-28 1982-01-05 Pfizer Inc. Oximino-1-hydroxyoctahydrobenzo[c]quinolines and derivatives thereof
SI0882021T1 (en) * 1996-01-31 2003-10-31 Altana Pharma Ag New phenanthridines

Also Published As

Publication number Publication date
BR9707233A (pt) 1999-07-20
PT882021E (pt) 2003-07-31
EA001205B1 (ru) 2000-12-25
DK0882021T3 (da) 2003-06-23
CY2473B1 (en) 2005-06-03
DE59709437D1 (de) 2003-04-10
EP0882021B1 (de) 2003-03-05
WO1997028131A1 (de) 1997-08-07
KR100454781B1 (ko) 2005-04-08
ES2194180T3 (es) 2003-11-16
CA2245142C (en) 2004-11-30
HU221380B1 (en) 2002-09-28
CZ289340B6 (cs) 2002-01-16
EA199800667A1 (ru) 1999-02-25
CA2245142A1 (en) 1997-08-07
JP4138003B2 (ja) 2008-08-20
EE03523B1 (et) 2001-10-15
US6191138B1 (en) 2001-02-20
EE9800223A (et) 1998-12-15
UA48216C2 (uk) 2002-08-15
EP0882021A1 (de) 1998-12-09
HUP9900666A3 (en) 2000-04-28
JP2000503996A (ja) 2000-04-04
ATE233735T1 (de) 2003-03-15
SI0882021T1 (en) 2003-10-31
KR19990082143A (ko) 1999-11-15
CZ241498A3 (cs) 1998-12-16

Similar Documents

Publication Publication Date Title
HUP9900666A2 (hu) Új fenantridinszármazékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
HUP9802822A2 (hu) Halogén-benzimidazol-származékok, intermedierjeik, előállításuk és a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
HUP9802304A2 (hu) Piridazin-3-on-származékok, intermedierjeik, alkalmazásuk, a vegyületeket hatóanyagként tartalmazó herbicid készítmények
CO5050332A1 (es) Composiciones fungicidas que comprenden 2-metoxibenzofenonas
MX9203165A (es) Derivados de succinimida y composicion farmaceutica que los contiene .
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
CY1110904T1 (el) Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun
HUP9700159A2 (hu) Benzil-szulfid-származékok, intermedierjeik, eljárás előállításukra és a vegyületeket hatóanyagként tartalmazó inszekticid készítmények
ES2143487T3 (es) 1,2,4-oxadiazolil-fenoxialquilisoxazoles y su empleo como agentes antivirales.
TR200000918T2 (tr) Halojen ikameli tetrasiklik tetrahidrofuran türevleri.
SE0201937D0 (sv) Therapeutic agents
FR2682381B1 (fr) Derives de benzodiazepine, leur preparation et les medicaments les contenant.
FI860111A0 (fi) Terapeutiska medel.
IL110979A (en) Substituted 17beta-anilide-4-aza-5alpha-androstan-3-ones their preparation and pharmaceutical compositions containing them
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
ATE49211T1 (de) Dreizyklische oxindole als antientzuendungsmittel.
IL110831A0 (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
NZ227400A (en) Thiol-ketone and thiol-aldehyde derivatives, intermediates thereof and pharmaceutical compositions
IE832109L (en) 1-arylcyclobutylalkylamine compounds
ATE52249T1 (de) Aminoalkyl-substituierte harnstoffderivate, deren saeureadditionssalze und enantiomere.
HUP9801229A2 (hu) Eljárás 5,6-dihidro-1,3-oxazin-származékok előállítására, intermedierjeik, hatóanyagként ezeket a vegyületeket tartalmazó inszekticid, arachnicid és nematocid készítmények és alkalmazásuk
MY103521A (en) Bicyclocatechol derivatives
BG102429A (en) Derivatives of 5-naphthalen-1-yl-1,3-dioxan, their preparation and usage as therapeutical means
NZ304988A (en) 1-omega-(3,4-dihydro-2-naphthalenyl)alkyl] cyclic amine derivatives and their use

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ALTANA PHARMA AG, DE

Free format text: FORMER OWNER(S): BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH., DE

MM4A Lapse of definitive patent protection due to non-payment of fees